Vaginal Progesterone in Twin With Short Cervix
Preterm Birth, Twin Dichorionic Diamniotic Placenta

About this trial
This is an interventional prevention trial for Preterm Birth focused on measuring Short cervix, twins, progesterone
Eligibility Criteria
Inclusion Criteria:
( All pregnant women known to have Dichorionic Diamniotic twins diagnosed on 12 week dating scan will be offered transvaginal ultrasound scan to assess cervical length at 20-24 week anomaly scan ) and so inclusion criteria include:
- ( Dichorionic Diamniotic twins ) and both twins are living .
- (Short Cervix 10-25mm) Diagnosed by transvaginal ultrasound scan between 20-24 weeks .
Exclusion Criteria:
1 - Cervical cerclage in place or planned . 2- on tocolytic drugs . 3- medically indicated preterm delivery < 35w of gestation . 4- known allergy to progesterone or peanuts ( as the active treatment contain peanut oil) .
5- known contraindication to progesterone
- Liver dysfunction or disease
- Known or suspected malignancy of breast or genital organs
- Active thromboembolic disorder , or history of hormone-associated thromboembolic disorder 6- known major structural or chromosomal fetal abnormality . 7- Rupture of fetal membranes (leakage of amniotic fluid one or both sacs)
Sites / Locations
- Ain Shams University, Maternity Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
progesterone
Placebo
74 patients will receive progesterone pessary 200mg twice daily
74 patients will receive placebo